Inserm-Transfert invests in TcLand
Paris-based Inserm-Transfert, a subsidiary of Inserm, has invested an undisclosed amount in TcLand, a biopharmaceutical company based in western France.
Paris-based Inserm-Transfert, a subsidiary of Inserm, has invested an undisclosed amount in TcLand, a biopharmaceutical company based in western France.
TcLand was founded in 2002 by scientists from the French Institut de Transplantation et de Recherche en Transplantation (ITERT), Europe's largest centre for kidney transplantation. The company is focused on new diagnostic and therapeutic strategies for organ transplant rejection and autoimmune diseases.
Inserm-Transfert, established in 2001, includes amont its objectives creating favorable conditions for the setting up of start-up companies based on science developed by France's national medical research institute, Inserm. In the last four years, and with the help of regional and national incubators, it has been involved in the creation of 10 biotechnology companies. These companies have already raised e85m through venture capital or industry partners.
'We were impressed by the quality of the scientific and management team at TcLand and the way in which they have matured since the creation of the company,' said Lionel Segard, Inserm-Transfert ceo. 'TcLand's technology opens up new possibilities in the control of organ transplant rejection and autoimmune diseases.'